- CIN
- U85110KA2009PLC050914
- ISIN
- —
- Incorporated
- 19 Feb 2009
- Registered state
- Karnataka
Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.
Business overview
Sundara Diagnostics Limited operates a pathology and radiology network of owned labs and franchise collection centres, concentrated in Karnataka, Tamil Nadu and Kerala with a reference lab in Bengaluru, running 42 labs and 2,180 collection points, processing 3.4 crore tests a year. The southern cluster strategy keeps logistics cost per sample among the lowest in the listed and unlisted diagnostics set, because samples reach a reference lab within a few hours. The company is currently in the pre-IPO stage, with a listing under active consideration, and shares change hands only through negotiated off-market transfers.
Key highlights
- Revenue per patient up 7% year on year
- Franchise model keeps capex per new collection point below ₹4 lakh
- Radiology added at 14 hub locations in FY2026
- No material regulatory proceedings disclosed
Financial snapshot
FY2026 · Audited · Source: Audited annual report
- Revenue FY2026
- ₹1,680.00 Cr
- EBITDA
- ₹462.00 Cr
- PAT
- ₹268.00 Cr
- Net worth
- ₹1,420.00 Cr
- Total debt
- ₹210.00 Cr
- Cash & equivalents
- ₹380.00 Cr
- Operating cash flow
- ₹412.00 Cr
- EPS
- ₹16.54
Management & board
- RASince 2020
Rakesh Agarwal
Managing Director & CEO
Has led Sundara Diagnostics since 2020 and previously held senior operating roles in the same sector.
- SJSince 2009
Sameer Joshi
Chief Financial Officer
- NSSince 2010
Neha Sinha
Executive Director — Operations
- SKSince 2013
Shalini Kulkarni
Company Secretary & Compliance Officer
Reported financials · FY2024–FY2026
Figures in ₹ crore unless stated. Every column carries its own source and audit status.
| Particulars | FY2026Audited | FY2025Audited | FY2024Audited | YoY |
|---|---|---|---|---|
| Profit & loss | ||||
| Revenue | ₹1,680 Cr | ₹1,410 Cr | ₹1,180 Cr | +19.1% |
| EBITDA | ₹462 Cr | ₹372 Cr | ₹294 Cr | +24.2% |
| Profit after tax | ₹268 Cr | ₹208 Cr | ₹156 Cr | +28.8% |
| Earnings per share | ₹16.54 | ₹12.84 | ₹9.63 | — |
| Balance sheet | ||||
| Net worth | ₹1,420 Cr | ₹1,180 Cr | ₹986 Cr | +20.3% |
| Total debt | ₹210 Cr | ₹240 Cr | ₹268 Cr | — |
| Cash & equivalents | ₹380 Cr | ₹296 Cr | ₹224 Cr | — |
| Total assets | ₹2,240 Cr | ₹1,920 Cr | ₹1,660 Cr | — |
| Book value per share | ₹87.65 | ₹72.84 | ₹60.86 | — |
| Cash flow | ||||
| Operating cash flow | ₹412 Cr | ₹338 Cr | ₹268 Cr | — |
Scroll the table sideways to see all columns
- FY2026 · Audited annual report · period ended 31 Mar 2026 · last updated in the back office 16 Sep 2026
- FY2025 · Audited annual report · period ended 31 Mar 2025
- FY2024 · Audited annual report · period ended 31 Mar 2024
Revenue, EBITDA and PAT
₹ crore. A year with no reported figure is left out rather than drawn as zero.
- Revenue
- EBITDA
- PAT
Every ratio on this tab is derived from the reported figures in the Financials tab and the indicative price in the header — nothing here is a stored value. A ratio that cannot be justified is shown as — with the reason, rather than as a negative or a zero. Ratios move when the indicative price moves.
Size
Balance-sheet items as at FY2026
- Market cap
- ₹20,493 Cr
- Enterprise value
- ₹20,323 Cr
- Indicative price
- ₹1,265
- Shares outstanding
- 16,20,00,000
Indicative price × shares outstanding
Market cap + debt − cash
Valuation multiples
- P/E
- 76.5x
- P/B
- 14.4x
- EV / EBITDA
- 44.0x
- EPS
- ₹16.54
- Book value / share
- ₹87.65
- Debt / equity
- 0.1x
On FY2026 PAT
Returns & margins
- ROE
- 18.9%
- ROCE (EBITDA basis)
- 28.3%
- EBITDA margin
- 27.5%
- PAT margin
- 15.9%
- Revenue growth
- 19.1%
- Cash / market cap
- 1.9%
EBITDA ÷ (net worth + debt)
Indicative price snapshots
Each point is a dated dealer-quote average. There is no continuous trading behind these numbers, so no daily series is drawn.
Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.
Snapshot log
| Date | Indicative price | Change | Source |
|---|---|---|---|
| 20 Sep 2026 | ₹1,265 | +1.89% | Dealer desk average, 4 quotes |
| 20 Aug 2026 | ₹1,242 | +3.31% | Dealer desk average |
| 20 Jul 2026 | ₹1,202 | +0.15% | Dealer desk average |
| 20 Jun 2026 | ₹1,200 | +0.95% | Dealer desk average |
| 20 May 2026 | ₹1,189 | +1.48% | Dealer desk average |
| 20 Apr 2026 | ₹1,171 | +1.26% | Dealer desk average |
| 20 Mar 2026 | ₹1,157 | +3.73% | Dealer desk average |
| 20 Feb 2026 | ₹1,115 | -0.56% | Dealer desk average |
| 20 Jan 2026 | ₹1,121 | +1.89% | Dealer desk average |
| 20 Dec 2025 | ₹1,101 | +3.63% | Dealer desk average |
| 20 Nov 2025 | ₹1,062 | +1.31% | Dealer desk average |
| 20 Oct 2025 | ₹1,048 | +0.67% | Dealer desk average |
| 20 Sep 2025 | ₹1,041 | — | Dealer desk average |
Scroll the table sideways to see all columns
Change is measured against the previous snapshot, not against a calendar period, because snapshots are not collected on a fixed schedule. The header percentages use fixed windows and may not tie exactly to this column.
Corporate actions & events
Dated events sourced from company filings and registrar records.
- Board9 May 2025
Appointment of an independent director
Board strengthened with an additional independent director following a nomination-committee review.
Company filing / RoC
- Split24 Mar 2025
Sub-division of equity shares
Face value sub-divided to improve tradability ahead of a listing.
Company filing / RoC
- Filing12 Jan 2025
Annual return filed with the registrar
Statutory filing completed within the prescribed timeline.
Company filing / RoC
IPO / listing status
- Current stage
- Pre-IPO
- DRHP filed
- —
- RHP filed
- —
- Expected window
- Not announced — under evaluation
- Registrar
- —
- Book-running managers
- —
Listing timelines are indicative and subject to regulatory approval and market conditions. A filing is not a guarantee of listing.
Lock-in applies after listing
Shares acquired before a public issue are typically subject to a statutory lock-in of six months from the date of listing. Confirm the applicable period before transacting.
Read the lock-in explainerResearch
Information currently unavailable
No research has been published on Sundara Diagnostics yet. Sector notes that mention it will appear here when they are.
Documents
Public documents open directly. Private documents are released to verified clients on request.
| Document | Type | FY / date | Source | Access |
|---|---|---|---|---|
| Annual Report FY20264.2 MB | Annual report | FY2026 | Company | Download |
| Annual Report FY20253.8 MB | Annual report | FY2025 | Company | Download |
| Audited financial statements — three-year summary620 KB | Financials | FY2024–FY2026 | Statutory filings | Download |
| Investor presentation9.1 MB | Presentation | 2026-07-15 | Company | On request |
Scroll the table sideways to see all columns
Risk assessment
Our own reading of the disclosed information. Treat the levels as judgement, not as fact.
Price competition
MediumOnline-first players discount aggressively in metro markets.
Geographic concentration
MediumThree states account for most of the revenue.
Risks common to every unlisted holding. You may not find a buyer when you want one, at any price. A listing may be delayed indefinitely or may never happen, and shares can list below the price at which they changed hands in the unlisted market. Disclosure by unlisted companies is thinner than by listed ones, and the indicative price is based on infrequent dealer quotes rather than continuous trading.